

OKLAHOMA BOARD OF NURSING
2915 North Classen Boulevard, Suite 524
Oklahoma City, Oklahoma 73106
405-962-1800

EXCLUSIONARY FORMULARY FOR ADVANCED PRACTICE REGISTERED NURSES
WITH PRESCRIPTIVE AUTHORITY

The Advanced Practice Registered Nurse (Certified Nurse Practitioner, Clinical Nurse Specialist and Certified Nurse Midwife) in accordance with Oklahoma Nursing Practice Act, may prescribe medications that are within the Advanced Practice Registered Nurse’s scope of practice, under the medical direction of a supervising physician and an Exclusionary Formulary. The Exclusionary Formulary lists medications or categories of medications that shall not be prescribed by the Advanced Practice Registered Nurse with deemed prescriptive authority through the Board. This authorization shall not include dispensing drugs, but shall not preclude, subject to federal regulations, the receipt of, the signing for, or the dispensing of professional samples to patients, in accordance with the Advanced Practice Registered Nurse’s scope of practice. The Advanced Practice Registered Nurse with prescriptive authority shall prescribe no more than a 30-day supply for Schedule III-V drugs. **All Schedule I and II Controlled Dangerous Substances cannot be prescribed by the Advanced Practice Registered Nurse with prescriptive authority. [63 O.S. § 2-312.C]**

Reference for the Exclusionary Formulary for Classification Purposes: *American Hospital Formulary Service Drug Information Book (current)*

The Exclusionary Formulary includes:

All Schedule I and II Controlled Dangerous Substances	
<p>28:04 <u>Anesthetics, General</u></p> <p>A. Barbiturates</p> <ul style="list-style-type: none"> • Sodium Methohexital (Brevital)* • Sodium Thiopental (Pentothal) (not in AHFS) <p>B. General Anesthesia Miscellaneous</p> <ul style="list-style-type: none"> • Etomidate (Amidate) <ul style="list-style-type: none"> ➤ <u>Exception:</u> May be ordered ONLY for Rapid Sequence Intubation by an APRN who is appropriately certified, privileged and credentialed • Fospropofol (Lusedra) • Ketamine (Ketalar) (not in AHFS) • Propofol (Diprivan) <p>C. Inhalation Anesthetics*</p> <p>All inhalation anesthetics including but not limited to the following:</p> <ul style="list-style-type: none"> • Nitrous Oxide • Cyclopropane • Ethylene • Sevoflurane (Ultane) • Desflurane (Suprane) • Enflurane (Ethrane) • Isoflurane (Forane) 	<p>28:08 <u>Analgesics</u></p> <p>A. Opiate Partial Agonist</p> <ul style="list-style-type: none"> • Buprenorphine (Suboxone, Bunavail, Probuphine)(with or without Naloxone) <ul style="list-style-type: none"> ➤ <u>Exception:</u> May be ordered for pain control, NOT for management of Narcotic dependency <p>B. Opiate Agonist</p> <ul style="list-style-type: none"> • Opium (Unless less than 25 mg/dosage unit) <p>28:16 <u>Psychotherapeutic Agents</u></p> <ul style="list-style-type: none"> • Clozapine <p>28:24 <u>Anxiolytics, Sedatives, Hypnotics</u></p> <p>A. Benzodiazepines</p> <ul style="list-style-type: none"> • Midazolam (Versed) <ul style="list-style-type: none"> ➤ <u>Exception:</u> May be ordered ONLY for Rapid Sequence Intubation by an APRN who is appropriately certified, privileged and credentialed

Board Approved: 10/23/96

OBN Policy/Guideline #P-50B

Board Reviewed w/o Revision: 11/19/98; 9/28/00; 11/16/05; 11/14/06; 9/25/07

Page 1 of 2

Board Revised: 11/17/99; 11/18/03; 9/23/08; 9/23/09; 11/8/11; 9/25/12; 11/4/13; 11/17/14; 9/29/15; 9/20/16

P:/Administration/Executive/Policies/Practice/P-50B Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority

<p>60:00 <u>Gold Compounds</u> All Gold Compounds including but not limited to:</p> <ul style="list-style-type: none"> • Auranofin (Ridaura)* • Aurothioglucose/Gold Sodium Thiomalate (Solganal, Aurolate)* 	<p>78:00 <u>Radioactive Agents*</u> All Radioactive Agents including but not limited to:</p> <ul style="list-style-type: none"> • Amyvid (not in AHFS)
--	---

The Advanced Practice Registered Nurse with prescriptive authority may submit to the Formulary Advisory Council a written request to amend to the Exclusionary Formulary with documentation verifying a practice-specific prescriptive standard(s). (See the *Formulary Advisory Council Procedure for Amending the Formulary* on the Oklahoma Board of Nursing's web site at: <http://www.ok.gov/nursing/prac-amndform.pdf>)

*Omitted from the print version of AHFS Drug Information because of space limitations. Updated drug information available on AHFS Drug Information website at: <http://www.ahfsdruginformation.com>



OFFICE OF ATTORNEY GENERAL
STATE OF OKLAHOMA

ATTORNEY GENERAL OPINION
2016-627A

Kim Glazier, Executive Director
Oklahoma Board of Nursing
2915 N. Classen Blvd., Ste. 524
Oklahoma City, Oklahoma 73106

November 2, 2016

Dear Executive Director Glazier:

This office has received your request for a written Attorney General Opinion regarding agency action that the Oklahoma Board of Nursing intends to take. The proposed action is to approve the following recommendations from the Formulary Advisory Council concerning modification of the exclusionary formulary: (1) deny a request to remove the drug Clozapine, (2) add the drug Probuphine, and (3) remove the drug Droperidol.

The Oklahoma Nursing Practice Act, 59 O.S.2011 & Supp.2015, §§ 567.1–567.20, authorizes the restriction of advanced practice registered nurses’ prescription authority through the creation of an “exclusionary formulary,” which lists drugs that may not be prescribed, 59 O.S.2011, § 567.4a(9)(a). The statute establishes a process whereby a Formulary Advisory Council recommends changes to the exclusionary formulary which changes must be approved by the Board before they go into effect. *See id.*

The decision to reject Clozapine’s availability for advanced practice registered nurses may be reasonable given that the drug has distribution restrictions—it can only be ordered through a National Registry system because of concerns with how it affects white blood cell counts and other adverse effects. Further, it is not clear that there is a compelling need for nurses, in addition to doctors, to be able to prescribe the drug.

The decision to add the drug Probuphine and remove the drug Droperidol may also be reasonable. Probuphine is a new Buprenorphine implant used to treat opioid dependence and Buprenorphine is already listed on the exclusionary formulary because of special prescribing requirements. Droperidol will be removed because it is no longer available.

It is, therefore, the official opinion of the Attorney General that the Oklahoma Board of Nursing has adequate support for the conclusion that the action advances the State of Oklahoma's policy to protect the public health, safety, and welfare.

A handwritten signature in black ink, appearing to read "E. Scott Pruitt". The signature is stylized with a large, sweeping initial "E" and a final flourish.

E. SCOTT PRUITT
ATTORNEY GENERAL OF OKLAHOMA